Prescient Therapeutics: PTX-100 targeted cell therapy briefing

December 18, 2023

Prescient Therapeutics: PTX-100 targeted cell therapy briefing

Prescient Therapeutics CEO and MD Steven Yatomi-Clarke gave a special investor briefing to discuss targeted cell therapy PTX-100.

In this session, he discussed:

  • The new PTX-100 Phase 1b clinical study results, following their unveiling at the American Society of Hematology (ASH) conference.
  • The next steps for PTX-100 including preparation for a meeting with the FDA to discuss using the Phase 2 trial as a registrational study.
  • The potential significance of accelerating approval and commercialisation of PTX-100 in an orphan disease.

Recorded on 18 December 2023 at 12:00pm (AEDT)

Join the next Prescient Therapeutics webcast

Register to stay up to date with Prescient Therapeutics

Featured Speaker

Steven Yatomi-Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.

Related Post

This investor centre was built by Reach Markets

©2022 Reach Markets

×

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
×

Any advice is general only

Any advice provided by Reach Markets, the Lead Manager on this offer, including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice.

×

Receive email updates

What is a 708 investor?

By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.